Physician profile
Danielle Gemignani
NPI 1750866984
$2,075.23
in general payments reported to CMS, 2019-2025
24 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,462 · 2022: $103 · 2023: $124 · 2024: $39.14 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $510.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.27 | 2021-2022 | |
| Janssen Biotech, INC. | $271.11 | 2021 | |
| Sun Pharmaceutical Industries INC. | $244.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $125.50 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $125.30 | 2021-2022 | |
| Boston Scientific Corporation | $125.00 | 2025 | Watchman Access System |
| Genzyme Corporation | $120.26 | 2021 | |
| Stryker Corporation | $97.37 | 2025 | Flowtriever |
| Alexion Pharmaceuticals, INC. | $95.20 | 2023 | Strensiq |
| Lilly USA, LLC | $74.50 | 2021 | |
| Leo Pharma INC. | $65.23 | 2021 | |
| Mayne Pharma Commercial LLC | $60.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $60.21 | 2021 | |
| Almirall LLC | $45.90 | 2021 | |
| Amgen INC. | $45.17 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $39.14 | 2024 | Abre |
| Genentech USA, INC. | $30.94 | 2021-2022 | |
| Philips North America LLC | $28.67 | 2023 | |
| Vyne Pharmaceuticals INC. | $24.47 | 2021 | |
| Organogenesis INC. | $24.14 | 2021 | |
| Smith+Nephew, INC. | $15.34 | 2021 | |
| Ucb, INC. | $14.38 | 2021 | |
| Incyte Corporation | $11.83 | 2021 | |
| Galderma Laboratories, L.P. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Gemignani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.